Long-term functional results must be the priority for subsequent studies by creating randomized controlled trials of over 2–3 years’ duration to evaluate GLP-1 RAs, SGLT2 inhibitors, and tirzepatide compared to robust measures of strength, physical performance, frailty, and incident sarcopenia, along with advanced body composition measures such as MRI/CT-based myosteatosis. This evidence concerns the gene GLP1R and sarcopenia.